Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Mahanor

Vascular Surgery Worcester, MA Medical Doctor

NPI 1013994755 CMS profile 318680

123 Summer St, Worcester, MA 01608

Open in the dashboard

General payments

$7,488

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Mahanor of Worcester, MA is reported in the CMS Open Payments database as having received $7,488 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $304 8
2024 General $739 17
2023 General $602 12
2022 General $2,474 39
2021 General $1,969 44
2020 General $712 27
2019 General $687 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Mahanor
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Elizabeth Mahanor were reported at $304. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Elizabeth Mahanor Vascular Surgery median Middle half National median
2019 $687 $796 $226–$2,363 $163
2020 $712 $348 $118–$1,110 $114
2021 $1,969 $471 $158–$1,421 $132
2022 $2,474 $725 $222–$2,183 $149
2023 $602 $836 $257–$2,440 $160
2024 $739 $909 $252–$2,619 $164
2025 $304 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $2,444 30 payments
  2. Boston Scientific Corporation $780 25 payments
  3. Janssen Pharmaceuticals, Inc $754 43 payments
  4. Endologix, Inc. $520 5 payments
  5. Veryan Medical Incorporated $445 3 payments
  6. Philips Electronics North America Corporation $408 7 payments
  7. W. L. Gore & Associates, Inc. $314 4 payments
  8. Smith+Nephew, Inc. $302 9 payments
  9. Bard Peripheral Vascular, Inc. $286 5 payments
  10. Sanara MedTech Inc. $144 1 payment
  11. Other $1,092 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,488 168 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Stent $2,292 28 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,292 28 payments
  3. XARELTO $875 45 payments
  4. ENHANCE Transcarotid Peripheral Access Kit $614 5 payments
  5. ENROUTE .014 Guidewire $614 5 payments
  6. BioMimics $410 2 payments
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $216 7 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $216 7 payments
  9. ENROUTE Transcarotid Neuroprotection System Cardiology Vascular Diseases $188 2 payments
  10. (4066) Tack Endo Sys ATK $173 2 payments
  11. Other $3,788 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

84

Median for Vascular Surgery: 122

Drug cost

$16,389

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 18 $15,379
Clopidogrel Clopidogrel Bisulfate Brand 66 $1,009

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$168,109

Medicare's payments for the services billed

Medicare patients

582

Average age 77

Services billed

1,713

316 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 48%
Chronic kidney disease 36%
Diabetes 30%
Atrial fibrillation 27%
Heart failure 25%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record